Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Recommendation of “Moderate Buy” by Analysts

Haleon PLC Sponsored ADR (NYSE:HLN) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company.

A number of equities research analysts have recently commented on HLN shares. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Argus upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a report on Thursday, April 30th.

Hedge Funds Weigh In On Haleon

Several institutional investors and hedge funds have recently modified their holdings of the company. Parkside Financial Bank & Trust raised its stake in Haleon by 101.3% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after purchasing an additional 1,433 shares during the period. Western Wealth Management LLC bought a new stake in shares of Haleon in the 1st quarter worth about $29,000. Annis Gardner Whiting Capital Advisors LLC increased its position in shares of Haleon by 402.0% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after purchasing an additional 2,404 shares during the last quarter. Atlantic Union Bankshares Corp boosted its holdings in shares of Haleon by 293.7% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after buying an additional 2,758 shares during the period. Finally, Stance Capital LLC acquired a new position in shares of Haleon in the 3rd quarter valued at about $34,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

Shares of HLN opened at $8.83 on Tuesday. Haleon has a 1-year low of $8.71 and a 1-year high of $11.42. The stock has a market cap of $39.09 billion, a PE ratio of 22.63, a price-to-earnings-growth ratio of 2.06 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The firm has a fifty day moving average price of $9.51 and a 200 day moving average price of $9.95.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The company had revenue of $3.65 billion during the quarter. As a group, sell-side analysts anticipate that Haleon will post 0.56 EPS for the current year.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.